Mario Ojeda‐Uribe

机构：Centre Hospitalier de Mulhouse · ORCID：0000-0001-6881-6055

发表论文 107 篇 · 总被引 1952 次 · h-index 22

代表论文

• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study (2023 · The Lancet · 被引 198)
• Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up (2020 · Blood Cancer Journal · 被引 59)
• Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy (2022 · Blood · 被引 39)
• Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study (2023 · Blood Advances · 被引 28)
• Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group (2021 · Blood · 被引 22)
• Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles (2019 · Blood · 被引 14)